SG11201811515WA - Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide - Google Patents
Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamideInfo
- Publication number
- SG11201811515WA SG11201811515WA SG11201811515WA SG11201811515WA SG11201811515WA SG 11201811515W A SG11201811515W A SG 11201811515WA SG 11201811515W A SG11201811515W A SG 11201811515WA SG 11201811515W A SG11201811515W A SG 11201811515WA SG 11201811515W A SG11201811515W A SG 11201811515WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- london
- methylbenzamide
- amino
- pyrazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1612240.0A GB201612240D0 (en) | 2016-07-14 | 2016-07-14 | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
PCT/GB2017/052056 WO2018011579A1 (en) | 2016-07-14 | 2017-07-13 | Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811515WA true SG11201811515WA (en) | 2019-01-30 |
Family
ID=56890600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811515WA SG11201811515WA (en) | 2016-07-14 | 2017-07-13 | Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
Country Status (18)
Country | Link |
---|---|
US (2) | US10934260B2 (es) |
EP (1) | EP3484471B1 (es) |
JP (1) | JP7094021B2 (es) |
KR (1) | KR102460529B1 (es) |
CN (1) | CN109414429B (es) |
AU (1) | AU2017294643B2 (es) |
BR (1) | BR112019000460A2 (es) |
CA (1) | CA3030622A1 (es) |
DK (1) | DK3484471T3 (es) |
ES (1) | ES2874661T3 (es) |
GB (1) | GB201612240D0 (es) |
HU (1) | HUE054539T2 (es) |
IL (1) | IL263908B (es) |
MX (1) | MX2019000385A (es) |
PL (1) | PL3484471T3 (es) |
PT (1) | PT3484471T (es) |
SG (1) | SG11201811515WA (es) |
WO (1) | WO2018011579A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201612240D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999057101A1 (en) | 1998-05-05 | 1999-11-11 | F. Hoffmann-La Roche Ag | Pyrazole derivatives as p-38 map kinase inhibitors |
NZ544230A (en) * | 2003-06-26 | 2009-07-31 | Novartis Ag | 5-Membered heterocycle-based P38 kinase inhibitors |
ES2605942T3 (es) * | 2012-03-20 | 2017-03-17 | Mereo Biopharma 1 Limited | Uso de un derivado de pirazol en el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva crónica |
JP6741773B2 (ja) | 2016-03-08 | 2020-08-19 | メレオ バイオファーマ 1 リミテッド | 炎症状態の急性増悪の治療のための投与レジメン |
MX2018010782A (es) | 2016-03-08 | 2019-01-10 | Mereo Biopharma 1 Ltd | Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica. |
GB201612240D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
-
2016
- 2016-07-14 GB GBGB1612240.0A patent/GB201612240D0/en not_active Ceased
-
2017
- 2017-07-13 WO PCT/GB2017/052056 patent/WO2018011579A1/en unknown
- 2017-07-13 PT PT177422789T patent/PT3484471T/pt unknown
- 2017-07-13 AU AU2017294643A patent/AU2017294643B2/en active Active
- 2017-07-13 IL IL263908A patent/IL263908B/en unknown
- 2017-07-13 MX MX2019000385A patent/MX2019000385A/es unknown
- 2017-07-13 ES ES17742278T patent/ES2874661T3/es active Active
- 2017-07-13 CN CN201780041222.XA patent/CN109414429B/zh active Active
- 2017-07-13 SG SG11201811515WA patent/SG11201811515WA/en unknown
- 2017-07-13 CA CA3030622A patent/CA3030622A1/en active Pending
- 2017-07-13 BR BR112019000460-2A patent/BR112019000460A2/pt unknown
- 2017-07-13 EP EP17742278.9A patent/EP3484471B1/en active Active
- 2017-07-13 PL PL17742278T patent/PL3484471T3/pl unknown
- 2017-07-13 US US16/317,012 patent/US10934260B2/en active Active
- 2017-07-13 JP JP2019501463A patent/JP7094021B2/ja active Active
- 2017-07-13 KR KR1020197001012A patent/KR102460529B1/ko active IP Right Grant
- 2017-07-13 HU HUE17742278A patent/HUE054539T2/hu unknown
- 2017-07-13 DK DK17742278.9T patent/DK3484471T3/da active
-
2021
- 2021-01-14 US US17/149,649 patent/US11434204B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2018011579A1 (en) | 2018-01-18 |
EP3484471B1 (en) | 2021-05-05 |
IL263908B (en) | 2022-07-01 |
US10934260B2 (en) | 2021-03-02 |
JP2019520420A (ja) | 2019-07-18 |
ES2874661T3 (es) | 2021-11-05 |
DK3484471T3 (da) | 2021-05-31 |
CN109414429B (zh) | 2021-09-14 |
CA3030622A1 (en) | 2018-01-18 |
KR102460529B1 (ko) | 2022-10-31 |
US20190352269A1 (en) | 2019-11-21 |
RU2019103880A (ru) | 2020-08-14 |
GB201612240D0 (en) | 2016-08-31 |
IL263908A (en) | 2019-01-31 |
BR112019000460A2 (pt) | 2019-04-24 |
JP7094021B2 (ja) | 2022-07-01 |
RU2019103880A3 (es) | 2020-09-29 |
US11434204B2 (en) | 2022-09-06 |
MX2019000385A (es) | 2019-05-23 |
PL3484471T3 (pl) | 2021-09-20 |
US20210206726A1 (en) | 2021-07-08 |
AU2017294643A1 (en) | 2019-01-17 |
HUE054539T2 (hu) | 2021-09-28 |
KR20190028432A (ko) | 2019-03-18 |
PT3484471T (pt) | 2021-06-02 |
CN109414429A (zh) | 2019-03-01 |
EP3484471A1 (en) | 2019-05-22 |
AU2017294643B2 (en) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810116VA (en) | Exosomes comprising therapeutic polypeptides | |
SG11201803900UA (en) | Process for preparing polyurea microcapsules with improved deposition | |
SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
SG11201901141WA (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201810366WA (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
SG11201804398XA (en) | Method for producing rna molecule compositions | |
SG11201808108XA (en) | Synthesis of indazoles | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201811706RA (en) | Process for the preparation of microcapsules | |
SG11201806485RA (en) | Pyrrolobenzodiazepine conjugates | |
SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201807540UA (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts | |
SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
SG11201407988UA (en) | Process for improved opioid synthesis | |
SG11201809630RA (en) | Nicotine particles | |
SG11201903417PA (en) | Ringing gel composition |